Alexander Y. Walley, MD

Associate Professor, Medicine

Alexander Walley
801 Massachusetts Ave Crosstown Center

Biography

Dr. Walley is the Director of the Boston University Addiction Medicine Fellowship Program and the Inpatient Addiction Medicine Consult Service at Boston Medical Center (BMC). He is a general internist and addiction expert who provides primary care for HIV-infected patients at BMC. His research interests include the medical complications of drug use, specifically HIV and overdose, the treatment of addictions with behavioral and pharmacologic interventions, and risk behaviors among HIV-infected people and people with HIV risk behaviors. He is an investigator on studies of the integration of addiction treatment into primary medical care and the implementation of an opioid overdose prevention programs.

He directs and founded a clinical program (FAST PATH) that integrates addiction treatment, into the medical care of patients who are HIV-infected or high-risk for HIV infection at Boston Medical Center. He founded the buprenorphine treatment program at Dimock Community Health Center in 2005. He previously served as the medical director of the Boston Public Health Commission methadone maintenance program. He is the medical director for the Massachusetts Department of Public Health’s Opioid Overdose Prevention Pilot Program. He completed a two year fellowship in general internal medicine in June 2007 and during that time he earned a Masters of Science degree in Epidemiology from BUSPH.

Other Positions

  • Courtesy Staff Privileges, Medicine, Boston Medical Center

Education

  • Johns Hopkins University School of Medicine, MD
  • Boston University School of Public Health, MSc
  • Harvard College, AB

Publications

  • Published on 2/8/2018

    Formica SW, Apsler R, Wilkins L, Ruiz S, Reilly B, Walley AY. Post opioid overdose outreach by public health and public safety agencies: Exploration of emerging programs in Massachusetts. Int J Drug Policy. 2018 Apr; 54:43-50. PMID: 29414484.

    Read at: PubMed
  • Published on 2/6/2018

    Lasser KE, Lunze K, Cheng DM, Blokhina E, Walley AY, Tindle HA, Quinn E, Gnatienko N, Krupitsky E, Samet JH. Depression and smoking characteristics among HIV-positive smokers in Russia: A cross-sectional study. PLoS One. 2018; 13(2):e0189207. PMID: 29408935.

    Read at: PubMed
  • Published on 12/5/2017

    Lorkiewicz SA, Ventura AS, Heeren TC, Winter MR, Walley AY, Sullivan M, Samet JH, Saitz R. Lifetime marijuana and alcohol use, and cognitive dysfunction in people with human immunodeficiency virus infection. Subst Abus. 2018 Jan 02; 39(1):116-123. PMID: 29058572.

    Read at: PubMed
  • Published on 12/4/2017

    Idrisov B, Lunze K, Cheng DM, Blokhina E, Gnatienko N, Quinn E, Bridden C, Walley AY, Bryant KJ, Lioznov D, Krupitsky E, Samet JH. Role of substance use in HIV care cascade outcomes among people who inject drugs in Russia. Addict Sci Clin Pract. 2017 Dec 04; 12(1):30. PMID: 29198185.

    Read at: PubMed
  • Published on 10/16/2017

    Kim TW, Walley AY, Ventura AS, Patts GJ, Heeren TC, Lerner GB, Mauricio N, Saitz R. Polypharmacy and risk of falls and fractures for patients with HIV infection and substance dependence. AIDS Care. 2018 Feb; 30(2):150-159. PMID: 29034725.

    Read at: PubMed
  • Published on 9/1/2017

    Edelman EJ, Lunze K, Cheng DM, Lioznov DA, Quinn E, Gnatienko N, Bridden C, Chaisson CE, Walley AY, Krupitsky EM, Raj A, Samet JH. HIV Stigma and Substance Use Among HIV-Positive Russians with Risky Drinking. AIDS Behav. 2017 Sep; 21(9):2618-2627. PMID: 28634662.

    Read at: PubMed
  • Published on 7/14/2017

    Kim TW, Walley AY, Heeren TC, Patts GJ, Ventura AS, Lerner GB, Mauricio N, Saitz R. Polypharmacy and risk of non-fatal overdose for patients with HIV infection and substance dependence. J Subst Abuse Treat. 2017 Oct; 81:1-10. PMID: 28847449.

    Read at: PubMed
  • Published on 7/4/2017

    Fairbairn N, Coffin PO, Walley AY. Naloxone for heroin, prescription opioid, and illicitly made fentanyl overdoses: Challenges and innovations responding to a dynamic epidemic. Int J Drug Policy. 2017 Aug; 46:172-179. PMID: 28687187.

    Read at: PubMed
  • Published on 7/3/2017

    Morgan JR, Schackman BR, Leff JA, Linas BP, Walley AY. Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population. J Subst Abuse Treat. 2018 Feb; 85:90-96. PMID: 28733097.

    Read at: PubMed
  • Published on 5/19/2017

    Lasser KE, Hanchate AD, McCormick D, Walley AY, Saitz R, Lin MY, Kressin NR. Massachusetts Health Reform's Effect on Hospitalizations with Substance Use Disorder-Related Diagnoses. Health Serv Res. 2017 May 19. PMID: 28523674.

    Read at: PubMed

View 67 more publications: View full profile at BUMC

View all profiles